A Guide To Dr. Clay Siegall

Have you ever heard of the name Clay Siegall? Well, have you ever heard of the name Dr. Clay Siegall? Unfortunately, many people in today’s society has never even heard of this wonderful man even though he has done so much for society. Clay Siegall is a cancer-research extraordinaire to the highest degree. He has an extended educational background, and he has attained numerous degrees in the process. In addition to that, Siegall has been the winner of numerous medical-related awards such as the Pacific Northwest Ernst & Young Entrepreneur of the Year Award. Lets dive a bit deeper into the life of Clay Siegall.

Dr. Clay Siegall started his professional career as a Senior Researcher for the affluent Bristol Myers Squibb. In addition to that, he has worked with other high-profile names such as the National Institute of Health. In 1998, Siegall co-founded a tiny startup company in Bothell, Washington. This company just so happened to be Seattle Genetics. This biotech-oncology company would end-up being the start to something new, especially when it came to fighting cancer. During the company’s early years of 1999 and 2000, it struggled to get a firm footing. Money was being spent faster than it was being earned, which resulted in big problems. Siegall and the small crew had to honker-down to get things in order. After implementing a dynamic sales staff, Seattle Genetics would finally catch its footing and the rest was history. To this very day, the sales staff of this phenomenal company is the actual face of the business.

In recent years, Seattle Genetics’ stock has tripled in a matter of a few years. Siegall has gone on to win multiple industry-related awards while holding onto 15 medical patents. What more can you say about this fantastic guy, and he’s looking to breakdown even more barriers in the future.

Clay Siegall; The Force Behind The ADC Technology

You can’t mention biotech leaders without mentioning Clay Siegall, the exceptional Chief Executive Officer of Seattle Genetics. He is, without a doubt, an asset to the medical community and has contributed a lot in the fight against the dreaded diseases like cancer. Through Seattle Genetics, Siegall introduced the first ADC technology, an innovation that led to the release of effective antibody-drug conjugates like ADCETRIS. Most of Siegall’s ADCs have attained the FDA approval and are used by many specialists for treatment around the world. ADCETRIS, for instance, has an enormous global impact and is accepted in more than 60 countries.

Siegall has been leading Seattle Genetics since its inception in 1998. Apart from being the CEO, the exceptional scientist is also the President and Chairman of the Board of Directors. As the CEO of the company, Siegall is responsible for advancement and promotion of the ADC technology. He also spearheads all the company’s fundraising activities. To date, Siegall has helped Seattle Genetics get more than $1.2 billion through various means of fundraising. This huge amount of money has allowed Seattle Genetics to make significant strides in the fight against cancer.

According to the latest news from Seattle Genetics, Siegall believes that there is more to be done, and he won’t slow down his enthusiasm and the dream of addressing the challenges associated with cancer once and for all. He spends most of his time conducting medical investigations. Currently, Siegall holds more than 15 patents that mainly focus on the topic of cancer treatments.

The remarkable CEO is also an author and has published more than 70 scientific articles. In these articles, Clay shares in-depth knowledge and research findings with scientists and the medical community. He is also the brains behind the top scientific journals, and he gives fellow scientists an opportunity to publish their medical articles. Siegall has received numerous awards throughout his career due to his scientific findings and leadership skills.

Siegall is a Ph.D. holder. He earned his B.S in Zoology from the University of Maryland. Before Seattle Genetics, Siegall worked at Bristol-Myers Squibb Pharmaceutical Research Institute until 1997.